A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

Clinical trials have shown that the RSV vaccine reduces symptoms by around 80 per cent, significantly lowering the risk of ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

A significant change is coming to GP surgeries, benefiting millions of people aged 75-79. The NHS is expanding its free ...

Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and ...

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...